Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Discontinuing GLP-1 use can result in rebound weight gain
Some patients experience mild nausea or injection site soreness initially
10.1002/ejhf.2115 16 BridgesH
Unlike traditional GLP-1 agonists, which primarily enhance insulin secretion and suppress appetite, Tirzepatide harnesses the additional effects of GIP, further improving metabolic control and promoting weight loss
Telehealth platforms can connect remote patients with prescribers while coordinating laboratory tests and pharmacy fulfillment closer to home
Increasing global obesity and diabetes burden Rising commercial demand for GLP-1 therapies Expansion of peptide manufacturing capacity Adoption of advanced peptide synthesis technologies Expansion into next-generation obesity and metabolic therapies Limited peptide manufacturing capacity and supply constraints Complexity of peptide synthesis and raw material availability The market is witnessing robust growth, driven by the rapidly increasing outsourcing demand for peptide active pharmaceutical ingredient (API) development and manufacturing associated with semaglutide and tirzepatide therapies
